Therefore, peptide FHAQNIHQTF derived from somatic mutation CIP2Ap.R229Q might be a potential CD8 T-cell target to a variety of cancer patients carrying this somatic mutation and corresponding HLA alleles (e.g., A∗24:02 and/or B∗39:01). Here, CD8A is linked to cancer.